SKYE BIOSCIENCE INC. - COMMON STOCK

Skye Bioscience Provides 2025 Look Ahead and Year in Review

13 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

19 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences

18 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

14 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

07 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

04 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Announce Third Quarter 2024 Results

01 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

29 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

21 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

23 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

26 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

23 Aug 2024 18:45:36 By Nasdaq GlobeNewswire

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

22 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

09 Aug 2024 17:59:37 By Nasdaq GlobeNewswire

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

24 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

11 Jul 2024 07:15:00 By Nasdaq GlobeNewswire

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

11 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

03 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes

01 Jul 2024 07:00:00 By Nasdaq GlobeNewswire